<SEC-DOCUMENT>0001213900-26-047736.txt : 20260427
<SEC-HEADER>0001213900-26-047736.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427074510
ACCESSION NUMBER:		0001213900-26-047736
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260427
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearmind Medicine Inc.
		CENTRAL INDEX KEY:			0001892500
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41557
		FILM NUMBER:		26896572

	BUSINESS ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
		BUSINESS PHONE:		972-54-5704749

	MAIL ADDRESS:	
		STREET 1:		101-1220 WEST 6TH AVENUE
		CITY:			VANCOUVER, BRITISH COLUMBIA
		STATE:			Z4
		ZIP:			V6H1A5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0287806-6k_clearmind.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: April 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-41557</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>CLEARMIND
MEDICINE INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>101 &ndash; 1220 West 6th Avenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vancouver, British Columbia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached hereto and incorporated herein is the
Registrant&rsquo;s press release issued on April 27, 2026, titled &ldquo;Clearmind Medicine Announces Evaluation of its Psychedelic-Based
Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea028780602ex99-1.htm">Press release titled: &ldquo;Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Clearmind Medicine, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: April 27, 2026</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;<I>Adi Zuloff-Shani</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Adi Zuloff-Shani</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028780602ex99-1.htm
<DESCRIPTION>PRESS RELEASE TITLED: "CLEARMIND MEDICINE ANNOUNCES EVALUATION OF ITS PSYCHEDELIC-BASED TREATMENT (MEAI) FOR POTENTIAL FDA BREAKTHROUGH THERAPY DESIGNATION"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><IMG SRC="ea028780602_ex99-1img1.jpg" ALT=""></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Clearmind
Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Positive clinical results from Alcohol Use Disorder&nbsp;clinical&nbsp;trial&nbsp;may&nbsp;strengthen
potential for&nbsp;eligibility for&nbsp;Breakthrough Therapy Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine
Inc. (Nasdaq: CMND) (&ldquo;Clearmind&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biotech company focused on the discovery and
development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,
today announced that it is evaluating its lead candidate, CMND-100 (MEAI), for eligibility for the U.S. Food and Drug Administration&rsquo;s
(FDA) Breakthrough Therapy Designation (BTD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are encouraged by the recognition and positive developments
in the space and are evaluating the suitability for potential Breakthrough Therapy Designation for CMND-100 based on the positive results
demonstrated to date throughout our ongoing FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder,&rdquo; said Dr. Adi Zuloff-Shani,
Ph.D., Chief Executive Officer of Clearmind Medicine. &ldquo;These data, combined with the recent Executive Order signed by President
Trump, which accelerates FDA review processes for certain psychedelic and neuroplastogen therapies designated as breakthrough treatments,
further support our belief that CMND-100 may meet the rigorous criteria for this important designation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA&rsquo;s Breakthrough Therapy Designation is granted to drugs
intended to treat serious or life-threatening conditions where preliminary clinical evidence indicates the potential for substantial improvement
over existing therapies on at least one clinically significant endpoints. Alcohol Use Disorder represents a life-threating with a significant
unmet medical need, affecting millions worldwide with limited effective treatment options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clearmind Medicine remains committed to science-driven development
and looks forward to continued engagement with the FDA as it advances CMND-100 toward providing safe, effective, and scalable non-hallucinogenic
treatment options for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of the date hereof, the Company has not submitted a request for
Breakthrough Therapy Designation for MEAI, and the FDA has not granted such designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About&nbsp;Clearmind&nbsp;Medicine Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech
company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve
widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s intellectual portfolio currently consists of nineteen
patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and
will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares of Clearmind are listed for trading on Nasdaq under the symbol
&ldquo;CMND.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, visit:&nbsp;https://www.clearmindmedicine.com&nbsp;or
contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations<BR>
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">invest@clearmindmedicine.com</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.Clearmindmedicine.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates&rdquo; and similar expressions
or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements
when it discusses its evaluation of the suitability for potential Breakthrough Therapy Designation for CMND-100, the timing and progress
of its clinical trials, its belief that CMND-100 may meet the rigorous criteria for Breakthrough Therapy Designation, its commitment to
science-driven development, and its continued engagement with the FDA as it advances CMND-100 toward providing safe, effective, and scalable
non-hallucinogenic treatment options for patients. Forward-looking statements are not historical facts, and are based upon management&rsquo;s
current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith.&nbsp;However, there can be no assurance that management&rsquo;s expectations, beliefs and projections
will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking
statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is&nbsp;made
to the Company&rsquo;s reports filed from time to time with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), including, but
not limited to, the risks detailed in the Company&rsquo;s annual report on Form 20-F for the fiscal year ended October 31,&nbsp;2025&nbsp;and
subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates
with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,
and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible
for the contents of third-party websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028780602_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028780602_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  7 )8# 2(  A$! Q$!_\0
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'BBJYF%C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
